A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019

April 12, 2020 updated by: Dong Yang, Jilin University
A study on the clinical and psychological characteristics of patients with coronavirus disease 2019 (COVID-2019)

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The main objective of this study is to study the clinical and psychological responses of patients with COVID-2019 during the whole treatment process. Including clinical symptoms, auxiliary examination results, and corresponding psychological changes, including depression, anxiety, insomnia, etc. This study will draw lessons about treatment and other better advices for other countries and regions.

Study Type

Observational

Enrollment (Anticipated)

132

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Jilin
      • Chang chun, Jilin, China, 130021
        • Recruiting
        • The First Hospital of Jilin University
        • Sub-Investigator:
          • Dong Yang, Master

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 80 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients with COVID-2019 would be observed.

Description

Inclusion Criteria:

  • patients with COVID-2019

Exclusion Criteria:

  • No

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
patients with COVID-2019
Patients with COVID-2019 would be observed.
Other: all treatment about COVID-2019
All patients with COVID-2019 would receive treatment provided by the government and should comply with relevant laws and regulations.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
fever
Time Frame: one month
The fever is one main clinical characteristics of patients with COVID-2019, Measured by thermometer. 37.2-38 degrees Celsius, low fever; 38-39 degrees Celsius, moderate fever; 39-40 degrees Celsius, high fever.
one month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
cough
Time Frame: one month
Cough is one main symptom of patients with COVID-2019. "Yes" or "no" would be recorded.
one month
diarrhea
Time Frame: one month
Diarrhea is one symptom of some patients with COVID-2019. "Yes" or "no" would be recorded.
one month
anxiety
Time Frame: two months
Anxiety is one main psychological characteristic of patients with COVID-2019. It would be assessed by Hamilton anxiety scale (HAMA). Scores of HAMA were positively correlated with the severity of anxiety.
two months
insomnia
Time Frame: two months
Insomnia is one main psychological characteristic of patients with COVID-2019. It would be assessed by Athens insomnia scale (AIS). Scores of AIS were positively correlated with the severity of insomnia.
two months
depression
Time Frame: two months
Depression is one psychological characteristic of patients with COVID-2019.It would be assessed by Hamilton Depression Rating Scale (HAMD) . Scores of HAMD were positively correlated with the severity of depression.
two months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jilin University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2020

Primary Completion (Anticipated)

June 1, 2020

Study Completion (Anticipated)

December 1, 2020

Study Registration Dates

First Submitted

April 6, 2020

First Submitted That Met QC Criteria

April 12, 2020

First Posted (Actual)

April 15, 2020

Study Record Updates

Last Update Posted (Actual)

April 15, 2020

Last Update Submitted That Met QC Criteria

April 12, 2020

Last Verified

April 1, 2020

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 130004

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-2019

Clinical Trials on all treatment about COVID-2019

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe